Theriva Biologics (TOVX) Receivables (2010 - 2026)
Theriva Biologics (TOVX) posted quarterly Receivables of $1.7 million for Q1 2026, up 0.83% year-over-year from $1.7 million in Q1 2025, and down 48.97% quarter-over-quarter from $3.4 million in Q4 2025.
Theriva Biologics (TOVX) Receivables (2010 - 2026) Analysis & Trends
Theriva Biologics (TOVX) has reported Receivables for 9 consecutive years, with $1.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Receivables rose 0.83% year-over-year to $1.7 million; the TTM figure through Mar 2026 stood at $1.7 million (up 0.83% YoY), while the FY2025 annual figure was $3.4 million, up 0.84% from the prior year.
- Receivables declined to $1.7 million in Q1 2026 per TOVX's latest filing, from $3.4 million in the prior quarter.
- Across five years, Receivables topped out at $3.4 million in Q4 2025 and bottomed at $1.6 million in Q3 2023.
- Historically, Receivables has averaged $2.1 million across 4 years, with a median of $1.9 million in 2024.
- Annual changes were most pronounced in 2024 — Receivables soared 71.29% — and 2025, when it decreased 11.11%.
- Theriva Biologics' Receivables stood at $1.9 million in 2023, then jumped by 71.29% to $3.3 million in 2024, then rose by 0.84% to $3.4 million in 2025, then slumped by 48.97% to $1.7 million in 2026.
- Business Quant data shows TOVX's Receivables at $1.7 million in Q1 2026, $3.4 million in Q4 2025, and $1.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.93 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 160.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.06 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 912.74 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 215.33 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 1.09 Bn |
| 10 | Theriva Biologics | 10.90 Mn | 10.90 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.70 Mn |
| Mar 31, 2026 | 1.71 Mn |
| Dec 31, 2025 | 3.35 Mn |
| Sep 30, 2025 | 1.82 Mn |
| Jun 30, 2025 | 1.77 Mn |
| Mar 31, 2025 | 1.70 Mn |
| Dec 31, 2024 | 3.32 Mn |
| Sep 30, 2024 | 2.00 Mn |
| Jun 30, 2024 | 1.93 Mn |
| Mar 31, 2024 | 1.91 Mn |
| Dec 31, 2023 | 1.94 Mn |
| Sep 30, 2023 | 1.58 Mn |
| Sep 30, 2017 | 742,000.00 |
| Jun 30, 2017 | 927,000.00 |
| Dec 31, 2016 | 185,000.00 |
| Dec 31, 2012 | 17,000.00 |
| Sep 30, 2012 | 122,000.00 |
| Jun 30, 2012 | 699,000.00 |
| Mar 31, 2012 | 440,000.00 |
| Dec 31, 2011 | 405,000.00 |